Hepatitis C vaccine - GeneCure Biotechnologies
Alternative Names: HCVax; Lentiviral based HCV immunotherapy - GeneCure Biotechnologies; Therapeutic HCV vaccine - GeneCure Biotechnologies; Therapeutic Hepatitis C virus vaccine - GeneCure BiotechnologiesLatest Information Update: 28 May 2023
At a glance
- Originator GeneCure
- Developer GeneCure Biotechnologies
- Class Antivirals; Hepatitis C vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Hepatitis-C in USA (SC)
- 20 Apr 2020 Phase-I clinical trials in Hepatitis C in USA (SC) (NCT04318379)
- 24 Mar 2020 Hepatitis C vaccine is available for licensing as of 24 Mar 2020. http://www.genecure.com/about-us.html